Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efbemalenograstim alfa for FN Prevention in Solid Tumors
NCT07187908Phase 2Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Jan 2025
- Primary completion
- Oct 2026
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of efbemalenograstim alfa in febrile neutropenia (FN), sponsored by Henan Cancer Hospital. Started Jan 2025; status: recruiting.
02
Drugs
efbemalenograstim alfa
03
Conditions
febrile neutropenia (FN)
Beyond the preview
Go deeper on NCT07187908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07187908.